Cofactor Genomics
In Brief This Week: Meridian Bioscience, BioMérieux, Applied DNA Sciences, More
News items for the week of Dec. 12, 2022.
The firm is aiming to commercialize its OncoPrism assay in 2023 as a laboratory-developed test to identify head and neck cancer patients eligible for checkpoint inhibitors.
Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay
The multi-center study is evaluating the use of Cofactor's OncoPrism test in predicting head and neck cancer patients' response to immunotherapy with other tumor types to follow.
The firm highlighted a new study exploring immune-related gene expression in ovarian cancer and gave an update on its lead diagnostic candidate for head and neck tumors.
Cofactor Genomics, UCSD Partner on Metastatic Head, Neck Cancer Study
The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.